WIWm. Larkin Iversen

Wm. Larkin Iversen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wm. Larkin Iversen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Structural covariance in the affective pain network in Alzheimer’s disease

    by Wm. Larkin Iversen, Todd B. Monroe, Michelle D. Failla

    Background: Pain consists of both sensory and affective networks. Literature exploring the effect of Alzheimer’s disease (AD) on pain is limited. Some evidence suggests that the affective networks are impacted earlier while the sensory networks are preserved until late in the course of disease (Cole 2006). To examine the preservation of networks underlying pain perception in AD, we examined the structural covariance of regions in the pain network. Using structural MRI (sMRI) data, we investigated structural covariance by modeling a network from the correlation of volume between regions. In structural covariance, path length represents the minimum number of steps that must be taken to travel between two nodes and may serve as a proxy for structural brain integrity. Characteristic path length averages together the path lengths for all nodes in a given a priori network to create a global network metric (Paldino 2017). We hypothesized that there would be alterations in altered characteristic and nodal path length in individuals with AD.Method: As part of a larger study, cortical volume measurements were obtained for 78 participants (39 AD, 39 HC) via Ma‐CRUISE mutli‐atlas segmentation (Huo 2016). The affective pain network consisted of bilateral: anterior and posterior insula, amygdala, anterior cingulate cortex (ACC), and dorsolateral pre‐frontal cortex (dlPFC, specifically the superior frontal and medial frontal gyri, Woo 2017). The analysis was conducted in BRAPH using a undirected weighted graph with negative correlations set to zero. (Mijalkov 2017). Only characteristic and nodal path length were included in this analysis as these metrics are more robust for discriminating differences in AD (Mårtensson 2018).Result: No significant differences were found for characteristic path length between groups (p = > 0.05). Additionally, no significant differences were found in path length for any of the nodes analyzed following correction with the Benjamini‐Hochberg procedure (Q = 0.05).Conclusion: Preservation of characteristic and nodal path length metrics in the affective pain network provides preliminary evidence that this network may be preserved in mild to moderate AD. This clinically meaningful finding provides further evidence indicate that affective pain may be preserved longer than originally thought during the course of AD.

  • Open Access

    Treating the most vulnerable: A discursive review of experimental pain in Alzheimer’s disease

    by Wm. Larkin Iversen, Ronald L. Cowan, Sebastian Atalla, Sydney S. Englehart, Tanya R. Gure, Karen O. Moss, Claire M. Ryan, Douglas W. Scharre, Kathy D. Wright, Todd B. Monroe

    Aim The purpose of this manuscript is to summarize research on how experimental pain is experienced by adults with Alzheimer's disease (AD) and to translate results into implications for nurses. Design This discursive review synthesizes the results of three previous research studies exploring experimental pain in adults with AD. Methods Using a series of fictional clinical vignettes, the authors discuss how the results from three previous papers using acute experimental pain can potentially be translated into clinical practice. The authors also introduce the reader to the concept of research-related psychophysics using introductory definitions and concepts with the impetus to encourage other nurses to consider this research methodology. Results Pain characteristics in AD that differ from cognitively intact controls must be explored to properly address pain in this population. Nurses are well positioned to address these issues in order to provide a high quality of care to adults with AD.


  • Open Access

    Experimentally evoked pain in Alzheimer's disease

    by Alison R. PhD(C) Anderson, W. Larkin Bs (Lab Supervisor) Iversen, Michael A. Dnsc Carter, Karen O. PhD Moss, Ronald L. Cowan, Todd B. PhD Monroe

    Background: Pain continues to be underrecognized and undertreated in Alzheimer's disease (AD) while existing guidance about pain assessment and management in dementia is not widespread. Brain regions involved in pain processing and modulation are damaged during AD, and the pain experience in AD is not well understood. Experimental pain studies using psychophysics can further our understanding of the pain experience in AD, which may lead to improved assessment and management of pain in people living with AD. Objective: A systematic review was conducted to explicate the current understanding of experimentally evoked pain in AD from primary research using psychophysical methods. Data Sources: Peer-reviewed publications were found via PubMed, CINAHL, and PsycINFO. A total of 18 primary research, peer-reviewed full articles that met inclusion criteria were included, representing 929 total participants. Conclusions: Experimentally evoked pain in people with AD demonstrates that despite cognitive impairment and a reduced ability to effectively communicate, individuals with AD experience pain similar to or more unpleasant than cognitively intact older adults. This may mean amplified pain unpleasantness in people with AD. Implications for practice: Our current best practices need to be widely disseminated and put into clinical practice. Self-report of pain continues to be the gold standard, but it is ineffective for noncommunicative patients and those unable to understand pain scales or instructions because of memory/cognitive impairment. Instead, pain treatment should be ethically initiated based on patient reports and behaviors, caregiver/surrogate reports, review of the medical record for painful conditions, analgesic trials, and regular reassessments.